Scientists discover new cell structure responsible for unexplained rejections after organ transplant

NewsGuard 100/100 Score

Drs. Marie-Josée Hébert and Mélanie Dieudé have discovered a new cell structure responsible for previously unexplained rejections following an organ transplant. They have also identified a drug capable of preventing this type of rejection. Recipients of the Award of Excellence in Research - Science Contribution of 2016 at the University of Montreal Hospital Research Center (CRCHUMM), they explain that this discovery could one day revolutionize transplant practice.

With the collaboration of the Canadian National Transplant Research Program, they continue their research to learn the language of organs.

Drs. Hébert and Dieudé have discovered a new cell structure responsible for previously unexplained rejections following an organ transplant. Before transplanting an organ, physicians check compatibility between the donor and recipient. Despite these precautions, approximately one in ten transplants ends up being rejected by the recipient.

"We have found the mechanism that causes a person to react against components in his own blood vessels even before receiving an organ transplant. We have also identified a drug capable of preventing this type of rejection," says Dr. Marie-Josée Hébert, transplant specialist and CRCHUM researcher. One day, this discovery could revolutionize transplant practice by changing the assessment of rejection risks in heart, lung, kidney or liver transplant recipients.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer